Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Stephan Koepke"'
Autor:
Verena Rombach-Riegraf, Anette C Karle, Babette Wolf, Laetitia Sordé, Stephan Koepke, Sascha Gottlieb, Jennifer Krieg, Marie-Claude Djidja, Aida Baban, Sebastian Spindeldreher, Atanas V Koulov, Andrea Kiessling
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e86322 (2014)
Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in the focus of intense discussions between health authorities, academics and biopharmaceutical companies in the context of concerns that such particles
Externí odkaz:
https://doaj.org/article/fa83ce637c2e4d06ac0092c6385922b6
Autor:
Jeffrey D. Kearns, Paul Wassmann, Ufuk Olgac, Marie Fichter, Brigitte Christen, Tina Rubic-Schneider, Stephan Koepke, Benjamin Cochin de Billy, David Ledieu, Cedric Andre, Stuart Hawtin, Benoit Fischer, Francesca Moretti, Christian Hug, Alexander Bepperling, Barbara Brannetti, Celia Mendez-Garcia, Amanda Littlewood-Evans, Andreas Clemens, Cynthia L. Grosskreutz, Pawan Mehan, Robert L. Schmouder, Vito Sasseville, Dominique Brees, Anette C. Karle
Publikováno v:
Science Translational Medicine. 15
Immunogenicity against intravitreally administered brolucizumab has been previously described and associated with cases of severe intraocular inflammation, including retinal vasculitis/retinal vascular occlusion (RV/RO). The presence of antidrug anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::646978bd4398a82aedbf85466acc67d5
https://doi.org/10.1126/scitranslmed.abq5068
https://doi.org/10.1126/scitranslmed.abq5068
Autor:
Anette C. Karle, Matthias B. Wrobel, Stephan Koepke, Michael Gutknecht, Sascha Gottlieb, Brigitte Christen, Tina Rubic-Schneider, Ingrid Pruimboom-Brees, Xavier Charles Leber, Meike Scharenberg, Benjamin Maciejewski, Oliver Turner, Chandra Saravanan, Francois Huet, Amanda Littlewood-Evans, Andreas Clemens, Cynthia L. Grosskreutz, Jeffrey D. Kearns, Pawan Mehan, Robert L. Schmouder, Vito Sasseville, Dominique Brees
Publikováno v:
Science Translational Medicine. 15
In October 2019, Novartis launched brolucizumab, a single-chain variable fragment molecule targeting vascular endothelial growth factor A, for the treatment of neovascular age-related macular degeneration. In 2020, rare cases of retinal vasculitis an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b253d859f72c25188df64a4808680e73
https://doi.org/10.1126/scitranslmed.abq5241
https://doi.org/10.1126/scitranslmed.abq5241